1,410 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter https://www.fool.com/investing/2017/07/16/pfizer-is-set-to-lose-its-no-1-spot-among-drugmake.aspx?source=iedfolrf0000001 Jul 16, 2017 - Novartis could take the top spot from Pfizer in prescription-drug sales by 2022. So what?
3 Reasons Gilead Sciences Jumped to Buy Kite Pharma https://www.fool.com/investing/2017/09/01/3-reasons-gilead-sciences-bought-kite-pharma.aspx?source=iedfolrf0000001 Sep 02, 2017 - If you're scratching your head over Gilead's $11.9 billion acquisition of the cancer-focused biotech, what management had to say about the deal should remove your confusion.
Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences https://www.fool.com/investing/2017/08/31/novartis-475000-price-tag-sets-the-stage-for-a-pri.aspx?source=iedfolrf0000001 Sep 01, 2017 - Ahead of Gilead Sciences completing its acquisition of CAR-T powerhouse Kite Pharma later this year, Novartis has secured FDA approval for its own CAR-T cancer therapy, and priced it at $475,000.
Chicago Bridge & Iron NV (CBI) Q2 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4097161-chicago-bridge-and-iron-nv-cbi-q2-2017-results-earnings-call-transcript?source=feed_all_articles Aug 10, 2017 - Chicago Bridge & Iron Co. NV (NYSE:CBI)Q2 2017 Earnings CallAugust 09, 2017 5:00 pm ETExecutivesW. Scott Lamb - Chicago Bridge & Iron Co. NVPatrick K. Mullen - Chicago Bridge & Iron Co. NVMichael S. T
3 Key Things Every CAR-T Investor Should Watch https://www.fool.com/investing/2017/07/25/3-key-things-every-car-t-investor-should-know.aspx?source=iedfolrf0000001 Jul 25, 2017 - The first CAR-T therapy recently won a unanimous thumbs up for approval. But that doesn't mean CAR-T stocks are out of the woods just yet.
Here Are the Big Pharma Stocks to Own Based on R&D Spending https://www.fool.com/investing/2017/08/27/here-are-the-big-pharma-stocks-to-own-based-on-r-2.aspx?source=iedfolrf0000001 Aug 27, 2017 - Roche, Novartis, Pfizer, Johnson & Johnson, and Merck are investing the heaviest in R&D. That could bode well for these big pharma stocks.
Are You Buying Gilead Sciences, Inc. for the Wrong Reason? https://www.fool.com/investing/2017/09/07/are-you-buying-gilead-sciences-inc-for-the-wrong-r.aspx?source=iedfolrf0000001 Sep 07, 2017 - The acquisition of Kite Pharma is a good move, but don't get caught up in the hype of Novartis' approval for Kymriah, which uses the same technology as Kite.
Here's Why the Best Is Yet to Come for Ionis Pharmaceuticals, Inc. https://www.fool.com/investing/2017/04/13/heres-why-the-best-is-yet-to-come-for-ionis-pharma.aspx?source=iedfolrf0000001 Apr 13, 2017 - A pipeline of drugs has this biotech poised for further success.
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale https://www.fool.com/investing/2017/09/14/exelixis-inc-and-bristol-myers-squibb-co-gear-up-f.aspx?source=iedfolrf0000001 Sep 14, 2017 - Ironically, round three could have the companies fighting on the same side.
NXP Semiconductors, NV: Steady Sailing Into the $38 Billion Qualcomm Buyout https://www.fool.com/investing/2017/05/15/nxp-semiconductors-nv-steady-sailing-into-the-38-b.aspx?source=iedfolrf0000001 May 15, 2017 - The first-quarter report saw adjusted earnings holding steady while organic sales increased by 7%.

Pages: 123456...141

Page 1>